Phase 3 HER2-negative Breast Cancer Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+3 more
Relay Therapeutics, Inc.540 enrolled192 locationsNCT06982521
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
HER2-negative Breast CancerER Positive Breast CancerStage III Breast Cancer+1 more
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled109 locationsNCT05512364
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
HER2-negative Breast CancerAdvanced Breast CancerER Positive Breast Cancer+1 more
MedSIR240 enrolled99 locationsNCT06382948
Recruiting
Phase 3
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+2 more
West German Study Group250 enrolled7 locationsNCT07281833
Recruiting
Phase 2Phase 3
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
HER2-negative Breast CancerNeoadjuvant Chemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University260 enrolled1 locationNCT04576143